New targeted radiation therapy shows promise for tough breast cancer
NCT ID NCT06590857
First seen Mar 08, 2026 · Last updated May 07, 2026 · Updated 5 times
Summary
This early-phase trial tests a drug called RYZ101 in people with a specific type of advanced breast cancer (ER+, HER2-) that has not responded to other treatments. The drug delivers radiation directly to cancer cells that have a certain marker (SSTR). The goal is to see if it is safe and can shrink tumors. About 16 participants will be enrolled.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Research Facility
Phoenix, Arizona, 85054, United States
-
Research Facility
Irvine, California, 92618, United States
-
Research Facility
San Diego, California, 92093, United States
-
Research Facility
Santa Monica, California, 90404, United States
-
Research Facility
Longmont, Colorado, 80504, United States
-
Research Facility
Jacksonville, Florida, 32224, United States
-
Research Facility
Atlanta, Georgia, 30322, United States
-
Research Facility
Indianapolis, Indiana, 46202, United States
-
Research Facility
Boston, Massachusetts, 02215, United States
-
Research Facility
Detroit, Michigan, 48202, United States
-
Research Facility
Rochester, Minnesota, 55905, United States
-
Research Facility
St Louis, Missouri, 63130, United States
-
Research Facility
Omaha, Nebraska, 68124, United States
-
Research Facility
Albuquerque, New Mexico, 87109, United States
-
Research Facility
Buffalo, New York, 14203, United States
-
Research Facility
New York, New York, 10016, United States
-
Research Facility
New York, New York, 10021, United States
-
Research Facility
Cleveland, Ohio, 44195, United States
-
Research Facility
Philadelphia, Pennsylvania, 19104, United States
-
Research Facility
Pittsburgh, Pennsylvania, 15213, United States
-
Research Facility
Dallas, Texas, 75246, United States
-
Research Facility
Houston, Texas, 77024, United States
-
Research Facility
Salt Lake City, Utah, 84132, United States
-
Research Facility
Norfolk, Virginia, 23502, United States
-
Research Facility
Seattle, Washington, 98109, United States
-
Research Facility
Victoria, British Columbia, V8R 6V5, Canada
-
Research Facility
Toronto, Ontario, M4N 3M5, Canada
-
Research Facility
Toronto, Ontario, M5G 2M9, Canada
-
Research Facility
Québec, Quebec, G1S 4L8, Canada
-
Research Facility
Seoul, Seoul, 03080, South Korea
-
Research Facility
Seoul, Seoul, 05505, South Korea
Conditions
Explore the condition pages connected to this study.